Oragenics

OGENPhase 2

Oragenics is striving to revolutionize neurological care through its proprietary intranasal delivery technology, which bypasses the blood-brain barrier to enable targeted, non-invasive brain therapeutics. The company's lead program, ONP-002, has completed Phase 1 safety studies for concussion and is preparing for Phase 2, with a broader pipeline including ONP-001 for rare leukodystrophies and a vaccine program. Oragenics is a public company (NYSE American: OGEN) positioning itself at the intersection of neurology and innovative drug delivery.

Market Cap

$3.1M

Focus

Biologics

OGEN · Stock Price

USD 0.75611.25 (-99.88%)

Historical price data

AI Company Overview

Technology Platform

Proprietary intranasal delivery platform leveraging olfactory/trigeminal nerve pathways to bypass the blood-brain barrier, combined with novel enantiomeric-neurosteroid chemistry for treating neurological conditions.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
Neurosteroid enantiomer	Mild Traumatic Brain Injury, Concussion	Phase 2
AG013	Oral Mucositis	Phase 2

Funding History

Total raised: $10M

IPO$10MUndisclosedFeb 11, 2014

Opportunities

First-to-market opportunity in the multi-billion dollar, untreated concussion market with ONP-002.

Platform expansion into large neurodegenerative disease markets (Alzheimer's, Parkinson's) and rare diseases.

NT-CoV-2 vaccine targets the evolving booster/variant market with a differentiated intranasal, needle-free profile.

Risk Factors

High clinical trial failure risk for lead candidate ONP-002.

Pre-revenue status and dependence on capital markets for funding create financial risk.

Navigating regulatory approval for a first-in-class concussion treatment is complex.

Intense competition in the COVID-19 vaccine market from large, established players.

Competitive Landscape

Faces limited direct competition in the nascent concussion drug market but competes with other biotechs exploring neuroprotection. In intranasal CNS delivery, competes with companies like Impel NeuroPharma. For COVID-19 vaccines, competes against giants (Pfizer, Moderna) and other intranasal candidates, differentiating on needle-free administration and mucosal immunity.